Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Debt: 2022-2025

Historic Total Debt for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $187.6 million.

  • Axsome Therapeutics' Total Debt fell 0.26% to $187.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.6 million, marking a year-over-year decrease of 0.26%. This contributed to the annual value of $189.0 million for FY2024, which is 2.45% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Total Debt stood at $187.6 million, which was up 0.05% from $187.5 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Total Debt peaked at $190.0 million during Q1 2025, and registered a low of $49.3 million during Q1 2022.
  • Over the past 3 years, Axsome Therapeutics' median Total Debt value was $186.4 million (recorded in 2024), while the average stood at $183.6 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Total Debt soared by 211.51% in 2023, and later dropped by 0.26% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Total Debt (Quarterly) stood at $100.2 million in 2022, then spiked by 84.18% to $184.5 million in 2023, then grew by 2.45% to $189.0 million in 2024, then declined by 0.26% to $187.6 million in 2025.
  • Its Total Debt was $187.6 million in Q3 2025, compared to $187.5 million in Q2 2025 and $190.0 million in Q1 2025.